Effect of DrOnedarone on atrial fibrosis progression and atrial fibrillation recurrence postablation: Design of the EDORA randomized clinical trial.
Nassir F MarroucheLilas DagherOussama WazniNazem AkoumMoussa MansourAbdel-Hadi El HajjarArezu BhatnagarHe Huanull nullPublished in: Journal of cardiovascular electrophysiology (2021)
EDORA will be the first trial to assess the progression of LA structural remodeling after ablation and its association with Dronedarone treatment and ablation success in a randomized controlled fashion. The trial will provide insight into the pathophysiology of AF recurrence after ablation and may provide potential therapeutic targets to optimize procedural outcomes.
Keyphrases
- catheter ablation
- atrial fibrillation
- left atrial
- phase iii
- left atrial appendage
- study protocol
- clinical trial
- oral anticoagulants
- phase ii
- radiofrequency ablation
- direct oral anticoagulants
- open label
- type diabetes
- left ventricular
- insulin resistance
- double blind
- coronary artery disease
- adipose tissue
- combination therapy
- venous thromboembolism
- placebo controlled
- replacement therapy